Pulmonary arterial hypertension: The burden of disease and impact on quality of life

European Respiratory Review

Volumn 24, Issue 138, 2015, Pages 621-629

  Delcroix, Marion ^a   Howard, Luke ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; MACITENTAN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; TADALAFIL; ANTIHYPERTENSIVE AGENT;

AEROBIC CAPACITY; CONCEPTUAL FRAMEWORK; DAILY LIFE ACTIVITY; EMOTIONALITY; EXERCISE TOLERANCE; HEMODYNAMICS; HUMAN; MUSCLE STRENGTH; PATIENT CARE; PHYSICAL ACTIVITY; PSYCHOSOCIAL CARE; PULMONARY HYPERTENSION; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SOCIAL SUPPORT; SURVIVAL RATE; TERMINAL CARE; VALIDATION PROCESS; WELLBEING; ARTERIAL PRESSURE; CAREGIVER; COMORBIDITY; COST OF ILLNESS; DRUG EFFECTS; HEALTH STATUS; HYPERTENSION, PULMONARY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PHILOSOPHY; PSYCHOLOGY; PULMONARY ARTERY; RISK FACTOR; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; CAREGIVERS; COMBINED MODALITY THERAPY; COMORBIDITY; COST OF ILLNESS; HEALTH STATUS; HOLISTIC HEALTH; HUMANS; HYPERTENSION, PULMONARY; PULMONARY ARTERY; QUALITY OF LIFE; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84951109213     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0063-2015     Document Type: Review

References (65)

1. Hoeper MM, Gibbs JSR. The changing landscape of pulmonary arterial hypertension and implications for patient care. Eur Respir Rev 2014; 23: 450–457.
2. Sanchez O, Marié E, Lerolle U, et al. Pulmonary arterial hypertension in women. Rev Mal Respir 2010; 27: e79–e87.
3. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2015 (in press); DOI: 10.1093/eurheartj/ehv317].
4. European Pulmonary Hypertension Association (PHA). The impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers: results from an international survey. www.phaeurope.org/wp-content/uploads/ International-PAH-patient-and-Carer-Survey-Report-FINAL1.pdf Date last updated: September 2012. Date last accessed: June 29, 2015.
5. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156–163.
6. Verma S, Cardenas-Garcia J, Mohapatra PR, et al. Depression in pulmonary arterial hypertension and interstitial lung diseases. N Am J Med Sci 2014; 6: 240–249.
7. Ulrich S, Fischler M, Speich R, et al. Wrist actigraphy predicts outcome in patients with pulmonary hypertension. Respiration 2013; 86: 45–51.
8. Corris P, Degano B. Severe pulmonary arterial hypertension: treatment options and the bridge to transplantation. Eur Respir Rev 2014; 23: 488–497.
9. Matura LA, McDonough A, Carroll DL. Health-related quality of life and psychological states in patients with pulmonary arterial hypertension. J Cardiovasc Nurs 2014; 29: 178–184.
10. Buys R, Avila A, Cornelissen VA. Exercise training improves physical fitness in patients with pulmonary arterial hypertension: a systematic review and meta-analysis of controlled trials. BMC Pulm Med 2015; 15: 40.
11. US Food and Drug Administration (FDA). The voice of the patient. A series of reports from the U.S. Food and Drug Administration’s (FDA’s) patient-focused drug development initiative. Pulmonary arterial hypertension. www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM429382.pdf Date last updated: December 2014. Date last accessed: August 17, 2015.
12. Taichman DB, Shin J, Hud L, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res 2005; 6: 92.
13. Wight JP, Edwards L, Brazier J, et al. The SF36 as an outcome measure of services for end stage renal failure. Qual Health Care 1998; 7: 209–221.
14. Hopman WM, Towheed T, Anastassiades T, et al. Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ 2000; 163: 265–271.
15. Harper R, Brazier JE, Waterhouse JC, et al. Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting. Thorax 1997; 52: 879–887.
16. Vanhoof JMM, Delcroix M, Vandevelde E, et al. Emotional symptoms and quality of life in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2014; 33: 800–808.
17. Löwe B, Gräfe K, Ufer C, et al. Anxiety and depression in patients with pulmonary hypertension. Psychosom Med 2004; 66: 831–836.
18. Shimony A, Eisenberg MJ, Rudski LG, et al. Prevalence and impact of coronary artery disease in patients with pulmonary arterial hypertension. Am J Cardiol 2011; 108: 460–464.
19. Ling Y, Johnson MK, Kiely DG, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 2012; 186: 790–796.
20. Tabarsi N, Levy R, Rychel V, et al. Pregnancy among women with pulmonary arterial hypertension: a changing landscape? Int J Cardiol 2014; 177: 490–491.
21. Jaïs X, Olsson KM, Barbera JA, et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J 2012; 40: 881–885.
22. Bédard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J 2009; 30: 256–265.
23. Tsangaris I. Improving patient care in pulmonary arterial hypertension: addressing psychosocial issues. J Clin Hypertens 2014; 16: 159–161.
24. Hwang B, Howie-Esquivel J, Fleischmann KE, et al. Family caregiving in pulmonary arterial hypertension. Heart Lung 2012; 41: 26–34.
25. Rival G, Lacasse Y, Martin S, et al. Effect of pulmonary arterial hypertension-specific therapies on health-related quality of life: a systematic review. Chest 2014; 146: 686–708.
26. de Jesus Perez VA, Rosenzweig E, Rubin LJ, et al. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. Am J Cardiol 2012; 110: 1546–1550.
27. Shafazand S, Goldstein MK, Doyle RL, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Chest 2004; 126: 1452–1459.
28. de Lartigue J. Oral treprostinil for the treatment of pulmonary arterial hypertension. Drugs Today 2014; 50: 557–565.
29. Sitbon O, Delcroix M, Bergot E, et al. EPITOME-2: an open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. Am Heart J 2014; 167: 210–217.
30. Subramaniyan G, Jain D, Lohiya B, et al. Recent advances in the management of pulmonary hypertension. Indian J Clin Pract 2014; 25: 414–415.
31. Safdar Z. Targeted oral therapies in the treatment of pulmonary arterial hypertension. Clin Drug Investig 2010; 30: 811–826.
32. Mandras SA, Gilkin RJ Jr, Pruett JA, et al. Pulmonary arterial hypertension: progress and challenges in the modern treatment era. Am J Manag Care 2014; 20: Suppl. 9, S191–S199.
33. Chen H, Taichman DB, Doyle RL. Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension. Proc Am Thorac Soc 2008; 5: 623–630.
34. US Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf Date last updated: December 2009. Date last accessed: May 6, 2015.
35. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–483.
36. EuroQoL Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199–208.
37. Hunt SM, McEwen J. The development of a subjective health indicator. Sociol Health Illn 1980; 2: 231–246.
38. McKenna SP, Doughty N, Meads DM, et al. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006; 15: 103–115.
39. Rector TS, Kubo SH, Cohn JN. Patients’ self-assessment of their congestive heart failure. Part 2: Content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Fail 1987; 3: 198–209.
40. Bonner N, Abetz L, Meunier J, et al. Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients. Health Qual Life Outcomes 2013; 11: 161.
41. Guyatt GH, Nogradi S, Halcrow S, et al. Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med 1989; 4: 101–107.
42. Yorke J, Corris P, Gaine S, et al. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J 2014; 43: 1106–1113.
43. Galen Research. Measures database. CAMPHOR – Language Adaptations Available. Available from: www.galenresearch.com/measures-database/ Date last accessed: October 22, 2015.
44. McCollister D, Kummer S, Badesch D, et al. Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: a new disease-specific patient-reported outcome instrument for PAH. Am J Respir Crit Care Med 2013; 187: A3294.
45. ClinicalTrials.gov. SYMPHONY: A Study of Macitentan in Pulmonary Arterial Hypertension to Validate the PAH-SYMPACT. https://clinicaltrials.gov/ct2/show/NCT01841762 Date last updated: 2015. Date last accessed: July 2, 2015.
46. ClinicalTrials.gov. A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain (ORCHESTRA). https://clinicaltrials.gov/ct2/show/NCT02081690 Date last updated: 2015. Date last accessed: July 2, 2015.
47. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010–3019.
48. Galiè N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093–2100.
49. Girgis RE, Frost AE, Hill NS, et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis 2007; 66: 1467–1472.
50. Mehta S, Channick RN, Delcroix M, et al. Macitentan improves health-related quality of life in pulmonary arterial hypertension: results from the randomized controlled SERAPHIN trial. Am J Respir Crit Care Med 2013; 187: A3269.
51. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296–301.
52. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322–329.
53. Simonneau G, Barst RJ, Galiè N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800–804.
54. Sastry BK, Narasimhan C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43: 1149–1153.
55. Pepke-Zaba J, Gilbert C, Collings L, et al. Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. Chest 2008; 133: 183–189.
56. Pepke-Zaba J, Beardsworth A, Chan M, et al. Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension. Curr Med Res Opin 2009; 25: 2479–2485.
57. Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330–340.
58. Howard LS, Ferrari P, Mehta S. Physicians’ and patients’ expectations of therapies for pulmonary arterial hypertension: where do they meet? Eur Respir Rev 2014; 23: 458–468.
59. Fernandes CJ, Martins BC, Jardim CV, et al. Quality of life as a prognostic marker in pulmonary arterial hypertension. Health Qual Life Outcomes 2014; 12: 130.
60. Batal O, Khatib OF, Bair N, et al. Sleep quality, depression, and quality of life in patients with pulmonary hypertension. Lung 2011; 189: 141–149.
61. Arena R, Cahalin LP, Borghi-Silva A, et al. The effect of exercise training on the pulmonary arterial system in patients with pulmonary hypertension. Prog Cardiovasc Dis 2015; 57: 480–488.
62. Fenstad ER, Shanafelt TD, Sloan JA, et al. Physician attitudes toward palliative care for patients with pulmonary arterial hypertension: results of a cross-sectional survey. Pulm Circ 2014; 4: 504–510.
63. Swetz KM, Shanafelt TD, Drozdowicz LB, et al. Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: results from a cross-sectional patient survey. J Heart Lung Transplant 2012; 31: 1102–1108.
64. Shipley J, Grinnan D, Swetz K, et al. The Health Care Initiative for Improving End of Life in Pulmonary Hypertension (CARING). Pulmonary Hypertension Association Online University. www.phaonlineuniv.org/ResourceLibrary/ Resource.cfm?ItemNumber=3680 Date last updated: September 22, 2011. Date last accessed: May 14, 2015.
65. Gihl A. Health-related quality of life in pulmonary arterial hypertension. Advances in PH 2010; 8: Winter 2010.